Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Supernus Pharmaceuticals, Inc. - Common Stock (NQ:SUPN)

42.18 -0.86 (-2.00%)
Delayed Quote Updated: 4:00 PM EDT, Oct 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 420,001
Open 43.21
Bid (Size) 16.97 (200)
Ask (Size) 59.50 (100)
Prev. Close 43.04
Today's Range 42.15 - 43.69
52wk Range 40.51 - 59.68
Shares Outstanding 53,145,884
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
1 Unprofitable Stock with Impressive Fundamentals and 2 We Avoid
Unprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around. Without a clear path to profitability, th... 
Via StockStory
News headline image
2 Growth Stocks to Add to Your Roster and 1 We Question
Growth is oxygen. But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived thr... 
Via StockStory
Topics Credit Cards

Performance

YTD
-14.7%
-14.7%
1 Month
-4.6%
-4.6%
3 Month
-11.0%
-11.0%
6 Month
-18.0%
-18.0%
1 Year
-11.7%
-11.7%

More News

Read More
News headline image
Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc. - SUPN
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
3 Reasons SUPN is Risky and 1 Stock to Buy Instead
Via StockStory
Topics Stocks Supply Chain
News headline image
Branded Pharmaceuticals Stocks Q2 Results: Benchmarking Supernus Pharmaceuticals (NASDAQ:SUPN)
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
3 Cash-Heavy Stocks Walking a Fine Line
Via StockStory
News headline image
1 of Wall Street’s Favorite Stocks with Promising Prospects and 2 Facing Headwinds
Via StockStory
News headline image
Supernus Pharmaceuticals to Participate in September Investor Conferences
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
3 Out-of-Favor Stocks We’re Skeptical Of
Via StockStory
News headline image
Chloe Kim Teams Up with Qelbree®, the #1 Prescribed Branded Non-Stimulant ADHD Treatment*, to Help Empower People Navigating ADHD
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
SUPN Stock Alert: Halper Sadeh LLC is Investigating Whether Supernus Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders
From Halper Sadeh LLC
Via Business Wire
News headline image
3 Small-Cap Stocks with Open Questions
Via StockStory
News headline image
1 Healthcare Stock with Exciting Potential and 2 We Ignore
Via StockStory
Topics Retirement
News headline image
Supernus Pharmaceuticals Reports Q2 2026 Results: Full Earnings Call Transcript ↗
Via Benzinga
Topics Earnings
News headline image
3 Russell 2000 Stocks We Approach with Caution
Via StockStory
News headline image
Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc. - SUPN
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
Why Supernus Pharmaceuticals Stock Topped the Market Today ↗
Via The Motley Fool
News headline image
Halper Sadeh LLC is Investigating Whether SUPN, ITGR, BOW are Obtaining Fair Deals for their Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
SUPN Stock Alert: Halper Sadeh LLC is Investigating Whether Supernus Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders
From Halper Sadeh LLC
Via Business Wire
News headline image
Supernus Pharmaceuticals Q2 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings
What's going on in today's pre-market session ↗
Via Chartmill
News headline image
Supernus Pharmaceuticals (NASDAQ:SUPN) Surprises With Q2 CY2026 Sales, Stock Jumps 24.9%
Via StockStory
News headline image
Supernus Announces Second Quarter 2026 Financial Results
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Supernus Pharmaceuticals and Indivior Pharmaceuticals to Merge, Creating a Diversified CNS Biopharmaceutical Leader with Significant Scale
From Supernus Pharmaceuticals, Inc.; Indivior Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Supernus Pharmaceuticals Earnings: What To Look For From SUPN
Via StockStory
Topics Artificial Intelligence

Frequently Asked Questions

Is Supernus Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Supernus Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Supernus Pharmaceuticals, Inc. - Common Stock trade on?
Supernus Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Supernus Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Supernus Pharmaceuticals, Inc. - Common Stock is SUPN on the Nasdaq Stock Market
What is the current price of Supernus Pharmaceuticals, Inc. - Common Stock?
The current price of Supernus Pharmaceuticals, Inc. - Common Stock is 42.18
When was Supernus Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Supernus Pharmaceuticals, Inc. - Common Stock was at 10/01/26 04:00 PM ET
What is the market capitalization of Supernus Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Supernus Pharmaceuticals, Inc. - Common Stock is 2.24B
How many shares of Supernus Pharmaceuticals, Inc. - Common Stock are outstanding?
Supernus Pharmaceuticals, Inc. - Common Stock has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.